TTYP01 is an investigational oral therapeutic developed by Shanghai Auzone Biological Technology Co., Ltd. The trial is evaluating TTYP01 tablets for the treatment of early symptomatic Alzheimer's disease. This is an international multi-center Phase 2 clinical trial.
| Attribute | Value |
|---|---|
| NCT Number | NCT07252440 |
| Phase | Phase 2 |
| Sponsor | Shanghai Auzone Biological Technology Co., Ltd. |
| Status | Recruiting |
| Participants | 180 |
| Study Start Date | 2024 |
| Estimated Completion | 2026 |
| Age Range | 50-85 years |
| Diagnosis | Early Symptomatic Alzheimer's Disease |
The trial employs a randomized, double-blind, placebo-controlled design to evaluate the safety, tolerability, and efficacy of TTYP01 in patients with early symptomatic Alzheimer's disease.
The specific mechanism of action for TTYP01 has not been publicly disclosed. Shanghai Auzone Biological Technology is a Chinese biotechnology company focusing on novel therapeutics for neurodegenerative diseases.
The focus on early symptomatic AD reflects the growing recognition that therapeutic interventions may be most effective in earlier disease stages when more neuronal tissue remains intact. The international multi-center design allows for broader patient recruitment and more diverse study populations.
The trial is being conducted at multiple centers internationally. Specific site locations are available on ClinicalTrials.gov.